Search Results for "budesonide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for budesonide. Results 1 to 10 of 21 total matches.
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma ...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3 doi:10.58347/tml.2024.1698a | Show Introduction Hide Introduction
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger's disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease ...
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos – Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn's disease of the ileum and/or ascending colon in
patients ≥8 years old and for maintenance of remission
for up to 3 months in adults. Ortikos is the second oral
formulation of budesonide to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first. A third oral formulation of budesonide
(Uceris) is approved for induction of remission in
patients with mild to moderate active ulcerative...
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
by inhibiting TPMT, especially in patients with inherited TPMT deficiency
Budesonide flSubstrate of CYP3A4 ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
) budesonide, is FDA-approved
for as-needed treatment or prevention
The Medical Letter publications ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92 doi:10.58347/tml.2024.1716a | Show Introduction Hide Introduction
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
associated with disease outweigh the low risk of adverse
pregnancy outcomes
Budesonide may result in lower ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
)
axis suppression
Budesonide causes less short-term corticosteroid toxicity
than prednisone
Can ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
Albuterol/budesonide – Airsurpa (Astra
Zeneca)
90/80 mcg/inh HFA MDI (120 inh/unit) 2 inh PRN (max 12 inh ...
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e192-5 doi:10.58347/tml.2024.1716b | Show Introduction Hide Introduction
Comparison Chart: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
▶ Pulmicort Flexhaler (budesonide)
Correct Use of Inhalers for Asthma (continued)
Instructions for Use ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8 doi:10.58347/tml.2024.1716c | Show Introduction Hide Introduction